Perspective Therapeutics (CATX) News Today $2.24 -0.06 (-2.39%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Perspective Therapeutics (NYSE:CATX) Earns "Outperform" Rating from WedbushMarch 28 at 1:23 AM | americanbankingnews.comScotiabank Sticks to Its Buy Rating for Perspective Therapeutics (CATX)March 27 at 10:50 PM | markets.businessinsider.comPerspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 ResultsMarch 27 at 10:50 PM | finanznachrichten.dePerspective Therapeutics (NYSE:CATX) Earns Outperform Rating from WedbushWedbush restated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Wednesday.March 27 at 8:24 PM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and BioMarin Pharmaceutical (BMRN)March 27 at 5:48 PM | markets.businessinsider.comPerspective Therapeutics Reports 2024 Earnings and Clinical ProgressMarch 27 at 12:06 AM | tipranks.comPerspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 ResultsMarch 26 at 4:10 PM | globenewswire.comPerspective Therapeutics (CATX) to Release Earnings on WednesdayMarch 24, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for CATX FY2025 Earnings?Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Perspective Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now anticipates that tMarch 22, 2025 | marketbeat.comHC Wainwright Has Negative Estimate for CATX FY2025 EarningsMarch 22, 2025 | americanbankingnews.comPerspective Therapeutics (NYSE:CATX) Earns "Buy" Rating from HC WainwrightMarch 21, 2025 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Perspective Therapeutics (NYSE:CATX)HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Wednesday.March 20, 2025 | marketbeat.comPerspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on WednesdayPerspective Therapeutics (NYSE:CATX) will be releasing earnings after the market closes on Wednesday, March 26, Financial Modeling Prep reports.March 19, 2025 | marketbeat.comWedbush Reiterates Outperform Rating for Perspective Therapeutics (NYSE:CATX)March 19, 2025 | americanbankingnews.comPerspective Therapeutics, Inc. Common Stock (CATX) Insider ActivityMarch 18, 2025 | nasdaq.comPerspective Therapeutics' (CATX) Outperform Rating Reiterated at WedbushWedbush reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday.March 18, 2025 | marketbeat.comPerspective Flat on New Drug TrialsMarch 17, 2025 | baystreet.caPerspective Therapeutics says first patient dosed in Phase 1/2a trial of VMT01March 17, 2025 | markets.businessinsider.comPerspective Therapeutics, Inc. Initiates First Patient Dosing in Phase 1/2a Trial of [212Pb]VMT01 for Melanoma TreatmentMarch 17, 2025 | quiverquant.comPerspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic MelanomaMarch 17, 2025 | globenewswire.comBrokers Set Expectations for CATX Q4 EarningsPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for Perspective Therapeutics in a report issued on Thursday, March 13th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.24) per share forMarch 15, 2025 | marketbeat.comPerspective Therapeutics (NYSE:CATX) Now Covered by HC WainwrightHC Wainwright started coverage on Perspective Therapeutics in a research report on Thursday. They set a "buy" rating and a $10.00 target price on the stock.March 14, 2025 | marketbeat.comPerspective Therapeutics (AMEX:CATX) Stock, Option ChainMarch 14, 2025 | benzinga.comPerspective Therapeutics initiated with a Buy at H.C. WainwrightMarch 14, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Perspective Therapeutics (CATX) with Buy RecommendationMarch 14, 2025 | msn.comPerspective Therapeutics (NYSE:CATX) Rating Increased to Strong-Buy at Brookline Capital ManagementBrookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a report on Monday.March 12, 2025 | marketbeat.comResearch Analysts Offer Predictions for CATX FY2024 EarningsPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a report issued on Monday, March 10th. Brookline Capital Management analyst K. Dolliver expects that the companyMarch 12, 2025 | marketbeat.comPerspective Therapeutics initiated with a Buy at BrooklineMarch 10, 2025 | markets.businessinsider.comPerspective Therapeutics, Inc. (NYSE:CATX) Given Average Rating of "Buy" by BrokeragesShares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have received a consensus rating of "Buy" from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, seven have given a buy rating and two haMarch 10, 2025 | marketbeat.comPerspective Therapeutics (NYSE:CATX) Upgraded by Lifesci Capital to Strong-Buy RatingLifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a report on Thursday.March 9, 2025 | marketbeat.comScotiabank Initiates Coverage of Perspective Therapeutics (CATX) with Sector Outperform RecommendationMarch 8, 2025 | msn.comPerspective Therapeutics (NYSE:CATX) Coverage Initiated by Analysts at ScotiabankScotiabank assumed coverage on Perspective Therapeutics in a report on Friday. They issued a "sector outperform" rating and a $15.00 price objective for the company.March 8, 2025 | marketbeat.comPerspective Therapeutics initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comCantor Fitzgerald Comments on CATX FY2024 EarningsPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of Perspective Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek forecasts that the company wMarch 7, 2025 | marketbeat.comPerspective Therapeutics (NYSE:CATX) Upgraded by Cantor Fitzgerald to "Strong-Buy" RatingCantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday.March 6, 2025 | marketbeat.comPerspective Therapeutics, Inc. Common Stock (CATX) SEC FilingsMarch 3, 2025 | nasdaq.comPerspective Therapeutics to Present at Upcoming March Investor ConferencesFebruary 26, 2025 | globenewswire.comPerspective Therapeutics, Inc. to Report Full Year 2024 Financial Results and Business Update on March 26, 2025February 21, 2025 | quiverquant.comPerspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial ResultsFebruary 21, 2025 | globenewswire.comPerspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of "Buy" from AnalystsPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy ratingFebruary 13, 2025 | marketbeat.comCantor Fitzgerald Weighs in on CATX FY2024 EarningsPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a report issued on Wednesday, February 5th. Cantor Fitzgerald analyst L. Watsek expects that the company will post earningsFebruary 7, 2025 | marketbeat.comPerspective Therapeutics to Participate in Upcoming February Investor ConferencesFebruary 5, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and iCAD (ICAD)January 27, 2025 | markets.businessinsider.comLucid raises Perspective Therapeutics stock target to $20January 27, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Axsome Therapeutics (AXSM) and HCA Healthcare (HCA)January 25, 2025 | markets.businessinsider.comPromising Clinical Developments and Strong Financial Position Reinforce ‘Buy’ Rating for Perspective TherapeuticsJanuary 24, 2025 | markets.businessinsider.comPerspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from WedbushWedbush reaffirmed an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Friday.January 24, 2025 | marketbeat.comPerspective continues to pursue dose escalation of 212PbVMT-alpha-NETJanuary 24, 2025 | markets.businessinsider.comPerspective Therapeutics, Inc. Announces Updated Interim Results from Phase 1/2a Study of [212Pb]VMT-α-NET in Neuroendocrine TumorsJanuary 24, 2025 | quiverquant.comPerspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers SymposiumJanuary 24, 2025 | globenewswire.com Remove Ads Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address CATX Media Mentions By Week CATX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CATX News Sentiment▼-0.160.78▲Average Medical News Sentiment CATX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CATX Articles This Week▼144▲CATX Articles Average Week Remove Ads Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IRMD News AVNS News BBNX News SIBN News KIDS News OM News TMCI News DCTH News SMLR News NPCE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CATX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for May 7th. Because on that day, I believe we could see a $2 Trillion shock INTO the ma...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
